Eosinophils are the white cells that drive allergic inflammation, and the count is used to phenotype asthma and to decide who responds to certain biologic drugs. A clinic in Shanghai checked what happened to that count in people prescribed semaglutide [1]. The exacerbation evidence is separate and is covered in the molecule that did not matter.
Counts fell. The median went from 160 to 110 per microliter, the eosinophil percentage from 2.20% to 1.60%, and the proportion of people sitting below the commonly used 150 threshold rose from 44.20% to 65.79%. Reductions appeared in people who started above the threshold and in those who started below it.
One result runs against the obvious explanation. The percentage reduction was larger in the lower-BMI group than the higher-BMI group, at -31.58% against -21.04% (P = 0.037). If the fall were simply a downstream consequence of losing weight, the people with more weight to lose would be expected to show the bigger drop. They did not, which points either at something other than weight or at the limits of a study this shape — the same inversion seen in the super-responder brand comparison.
For a buyer the practical content is thin but not zero. If you have eosinophilic asthma and your counts are being used to decide about a biologic, a GLP-1 drug may be moving the number your specialist is reading. That is worth mentioning rather than assuming it is irrelevant, in the same way the pressure settings in nobody is rechecking your CPAP are worth raising.
Nothing here suggests buying one of these drugs for asthma, and nothing here suggests avoiding one because of it. What it adds is one more entry in a growing list of laboratory values these drugs move without anyone having established what the movement means — a pattern also visible in responding is not one thing.